文献速递临床试验与 GCP

高剂量调强质子治疗对比标准剂量调强放射治疗食管鳞状细胞癌(HI-SIRI):一项随机对照临床试验的研究方案

High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial.
PubMed 文献 · Trials · 2022-10-22

本研究为双臂开放标签II/III期多机构随机对照试验,拟纳入232例胸段食管鳞状细胞癌患者,按可切除性分层后1:1随机接受调强质子治疗(IMPT)或调强放射治疗(IMRT)。II期阶段每组40例评估安全性与可行性,III期阶段每组再纳入76例比较无进展生存期,次要终点包括总生存、局部和远处控制、毒性、健康相关生活质量和成本效用。

要点

  • 胸段食管鳞癌患者按可切除性分层后1:1随机接受IMPT或IMRT。
  • II期每组40例评估毒性和术后并发症及招募率、放化疗剂量调整。
  • III期每组再纳入76例,主要比较无进展生存期。

核心结论

  • 该随机临床试验将展示IMPT在食管癌治疗中生存和毒性结局方面的临床获益,为胸段食管鳞状细胞癌的放射治疗模式进一步确立高级别证据。

研究设计与样本

  • 双臂开放标签II/III期多机构随机对照试验,计划共纳入232例组织学确诊的胸段食管鳞状细胞癌患者。
  • 按可切除性状态(可切除 vs 临界可切除/不可切除)分层后,按1:1比例随机分配接受IMPT或IMRT。
  • 可切除病例在医学上适合手术时尝试同步放化疗后手术切除;初始临界可切除/不可切除者行根治性同步放化疗。
  • II期阶段每组40例评估安全性(毒性和术后并发症)和可行性(招募率和放化疗剂量调整)。
  • III期阶段每组再招募76例,比较IMPT组与IMRT组的无进展生存期。

主要发现

  • II期阶段每组40例评估安全性和可行性。
  • III期阶段每组再招募76例,比较IMPT组与IMRT组的无进展生存期。
  • 次要终点包括总生存、局部和远处控制、毒性、健康相关生活质量和成本效用。

关键数值与推荐

  • 入组标准为组织学确诊的胸段食管鳞状细胞癌,无气管食管瘘/食管支气管瘘或远处转移证据。
  • 按可切除性状态(可切除 vs 临界可切除/不可切除)进行分层。
  • 随机分配比例为1:1。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Chemoradiotherapy is the standard of care for esophageal cancer as a neoadjuvant treatment before surgery, or as a definitive treatment for unresectable disease. Intensity-modulated radiotherapy (IMRT) has been considered the standard radiation technique. However, patients suffer from treatment-related toxicities, and most die from disease progression or recurrence. With emerging technological advancement, proton therapy has theoretical advantages over IMRT because it offers apparent dosimetric benefits to allow dose escalation to the target while better sparing surrounding tissues such as the lungs, heart, liver, and spinal cord. The purpose of this study protocol is to investigate the survival benefit of proton therapy using modern intensity-modulated proton therapy (IMPT) compared to standard IMRT for esophageal cancer. METHODS: This is a two-arm open phase II/III multi-institution randomized controlled trial. Eligible patients will have histologically confirmed squamous cell carcinoma of the thoracic esophagus with no evidence of tracheoesophageal/esophagobronchial fistula or distant metastasis. After stratification according to resectability status (resectable vs. borderline resectable/unresectable), a total of 232 patients will be randomized to receive IMPT or IMRT using a 1:1 allocation ratio. In resectable cases, surgical resection following concurrent chemoradiation will be attempted for the patients who are medically fit at the time of surgery. In those with initially borderline resectable/unresectable disease, definitive concurrent chemoradiation will be performed. The phase II study will assess safety (toxicity and postoperative complications) and feasibility (recruitment rate and chemoradiation dose modification) in 40 patients into each arm. The study will then continue into phase III, further recruit 76 patients into each arm, and compare progression-free survival between IMPT vs IMRT groups. The secondary endpoints will be overall survival, local and distant control, toxicities, health-related quality of life, and cost-utility. This protocol describes a detailed radiotherapy and chemotherapy. DISCUSSION: This randomized clinical trial will demonstrate the clinical benefit of IMPT in esophageal cancer treatment in terms of survival and toxicity outcomes which will further establish high-level evidence for radiation modality in squamous cell carcinoma of the thoracic esophagus. TRIAL REGISTRATION: TCTR20200310006 . Registered 10 March 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Lertbutsayanukul C, Kitpanit S, Kannarunimit D, et al. High-dose Intensity-modulated proton therapy versus Standard-dose Intensity-modulated RadIation therapy for esophageal squamous cell carcinoma (HI-SIRI): study protocol for a randomized controlled clinical trial. Trials. 2022. PMID: 36273186. doi:10.1186/s13063-022-06822-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。